All News
The RheumNow Week in Review – Cocoon Therapy? (7.20.18)
Dr. Jack Cush reviews highlights from the news and social media on RheumNow.com in the past week.
Read Article
Systemic Sclerosis: More Common than Expected
Systemic sclerosis is more common in the United Kingdom than previously reported, a nationwide population-based study determined.
Read Article
The RheumNow Week in Review – Baricitinib Splash (6.7.18)
Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.
Read Article
SPAR Predicts ILD Progression in Systemic Sclerosis
The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding.
Read Article
The RheumNow Week in Review – Why Comorbidity is Like the Weather (5.3.18)
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
Read Article
The Consequences and Cure of Hepatitis C
I spent this past week seeing hepatitis C patients with our hepatologists, and being a rheumatologist, I was looking forward to seeing extra-hepatic manifestations of HCV that we read about in text-books - cryoglobulinemic vasculitis, sicca syndrome, porphyria cutanea tarda and many others. I suppose I should not be surprised that the week passed without seeing a single one of these.
Read Article
Abatacept Improves GvHD Outcomes
The results from a phase 2 clinical trial presented at the American Society of Hematology meeting demonstrated that the drug abatacept was highly effective in managing severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.
Read Article
The RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article
Nailfold Capillaroscopy Portends Prognosis in Systemic Sclerosis
Two reports underscore the importance of nailfold capillaroscopy (NFC) in scleroderma and have shown that nailfold capillary drop out was significantly associated with mortality in systemic sclerosis.
Read Article
The RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read Article
Inefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD
EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged
Read Article
The RheumNow Week in Review - 5 January 2018
Dr Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
Stem Cell Transplant Succeeds in Scleroderma
Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.
Read Article
Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's
The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.
Read Article
Fatigue, HAQ and Hand Disability Correlated in Early Systemic Sclerosis
Early diffuse cutaneous systemic sclerosis (SSc) was associated with high levels of disability and fatigue, according to analysis of data from the European Scleroderma Observational Study cohort.
Read Article
The ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read Article
Key Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read Article
Tocilizumab Benefits Persist in SSc
Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.
Read Article
13 October 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!
Read Article